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Myasthenia gravis (MG) is a treatable autoimmune disease 
in which the autoantibody is directed at the acetylcholine 
receptor (AChR) on the postsynaptic neuromuscular junc-
tion.  AChR antibodies are identifiable in 85 - 90% of patients 
with generalised myasthenia, and are highly specific for MG.1,2 
Traditionally MG was viewed as a disease of young women, in 
whom it may be associated with other autoimmune diseases, 
specific HLA subtypes (HLA-B8, DR3), and the presence of thy-
mic enlargement (reviewed elsewhere3,4).  In recent years the 
incidence and prevalence of MG in the middle-aged and older 
population have been found to be higher than expected,4-7 and 
there is literature to suggest that the true incidence in the elder-
ly is still underestimated.8  In late-onset MG, with presentation 
after the age of 50 years,9 the thymus is usually normal and 
there is a weak and different HLA association.9,10  Moreover, 
there is a near-equal sex incidence in the older age group.9,10
Current estimates from North America suggest the 
prevalence of MG to be about 19 - 21 per 100 000 population.5 
There has been a substantial increase in diagnosis in older age 
groups,4 with those over the age of 50 years constituting up to 
60% of newly diagnosed seropositive MG (SPMG) cases.3  The 
incidence of MG has been found to be similar across racial 
groups, although one study11 found a trend towards a higher 
incidence in young African-Americans from Virginia.  No 
epidemiological data on SPMG are available for Africa. The 
aims of this study were therefore to determine the incidence 
rates (IRs) of SPMG in Cape Town (CT) and an overall crude 
IR for the whole of South Africa (SA), and to compare these 
findings with IRs in other countries.   
Patients and methods
Only two laboratories in SA perform the AChR assay, namely 
the state-run Allergology Laboratory at the University of 
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Background. Myasthenia gravis (MG) is a treatable autoimmune 
disease characterised by fatiguable weakness of skeletal 
muscles.  More than 85% of MG patients have antibodies to the 
acetylcholine receptor (AChR) at the neuromuscular junction 
or are seropositive for MG (SPMG).  In the developed world 
the incidence of MG has increased, particularly among older 
individuals, but no epidemiological studies have been done on 
SPMG in Africa.
Objectives. To determine the annual incidence rate (IR) of SPMG 
in the Cape Town (CT) municipality, and the crude annual IR 
of SPMG for the whole of South Africa (SA).  
Methods.  Positive AChR antibody tests were identified between 
1 January 2003 and 1 January 2005 for patients living in CT, 
and the age- and sex-specific incidences were calculated. To 
determine the national crude annual IR over the same period, 
positive assays were identified from the laboratories that 
process AChR assays for SA. National Census 2001 population 
statistics formed the denominators.
Results. There were 65 positive assays in CT, and 230 nation-
wide. Based on these figures the annual IR for CT was 11.2 per 
million per year (95% confidence interval (CI) 8.7 - 14.3), and 
for South Africa 2.6 per million/year (95% CI 2.2 - 2.9). After 
a questionnaire response from CT neurologists regarding the 
routine use of the AChR antibody assay, the annual IR for CT 
was adjusted to 12.6 per million (95% CI 9.9 - 15.9) to incor-
porate those presumed to have SPMG without a confirmatory 
test.  In CT, the IR in females was 15.3 per million/year (95% 
CI 11.2 - 20.4), and in males, 6.8 per million/year (95% CI 4.1 - 
10.7). The CT IRs for blacks, coloureds and whites were not 
statistically different after adjusting for age and gender.  The 
IR of SPMG in CT was 6 times greater in those presenting after 
the age of 50 years than in those with earlier disease onset (95% 
CI 3.7 - 9.7). 
Conclusions. The annual IR of SPMG in CT is much the same 
as rates recorded recently in other developed countries, but 
the rest of SA has a much lower IR.  A preponderance of MG 
starting after the age of 50 years reflects a worldwide trend, 
although the CT data showed a relatively lower-than-expected 
incidence for older males. IRs for SPMG vary widely in 
different regions in SA; this is likely to be related to differences 
in regional health care delivery, and underdiagnosis.
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Cape Town (UCT), and a private laboratory (Drs Du Buisson, 
Bruinette & Kramer Laboratories Inc.) in Pretoria.  To calculate 
the IR for CT, all positive AChR assays processed by these 
two laboratories from 1 January 2003 to 1 January 2005 were 
included; all positive AChR assays from UCT were included 
if the patients concerned lived within the CT municipality as 
defined by the national Census 2001 demarcations, and positive 
assays from the private laboratory were included only if the 
requesting doctor practised in CT. Age and sex were obtained 
from the laboratory records.  A positive AChR assay included 
values >0.2 nmol/l for assays done at the UCT laboratory, and 
values >0.5 nmol/l for assays done at the private laboratory, 
according to the assay conditions of the different commercial 
kits used by the two laboratories.  
Records of state patients attending the UCT myasthenia 
gravis clinic (UCT-MG) at Groote Schuur Hospital (GSH) were 
reviewed to ascertain residential address, age at diagnosis, 
sex, and race. Data on race were derived from the records in 
accordance with Statistics South Africa Census categories, viz. 
black, white, coloured, and Indian/Asian, and were available 
for the UCT-MG cohort.  Demographic data were incomplete 
for the patients assayed at the private laboratory.  A small 
number of assays of subjects resident in KwaZulu-Natal and 
Gauteng were tested in a third laboratory, the Neurosciences 
Laboratory in Oxford, UK. Results were obtained for this 
subset, but no age, sex or race data. A crude annual IR was 
calculated for the whole country based on the positive assays 
from all three laboratories between 1 January 2003 and 1 
January 2005.  
A questionnaire (not shown) was sent to all private 
neurologists in CT. This was used to ascertain the number of 
patients they had diagnosed with MG over the 2-year study 
period and how often the AChR test was requested when MG 
was clinically suspected.  The results of the questionnaire were 
used to adjust the calculated IR for CT in an attempt to correct 
for underdiagnosis.
Data were collected over 2 years and the results were 
averaged to reduce the possible bias of a small sample.  
Permission to perform this study was obtained from the UCT 
Research Ethics Committee (REC REF: 418/2004). 
Statistical analysis
IRs were calculated using denominators derived from the 
Statistics South Africa Census (2001).12 Confidence intervals 
(CIs) for IR were estimated using the Poisson distribution. 
IR ratios (IRRs) between different subgroups were calculated 
using the Poisson regression analysis.  
Results
The two SA laboratories processed a total of 1 024 specimens 
over the 2-year study period; 120 of the 774 assays performed 
by the private laboratory were positive (range 0.61 - 15.49 
nmol/l) and 69 of 250 assays from the UCT laboratory were 
positive (0.29 - 16.64 nmol/l). There were 65 recorded positive 
assays from within the CT municipality in the 2-year study 
period.  Since the total population in the CT municipality in 
2001 was 2 893 251 (national Census figures),12 the overall IR in 
CT was 11.2 cases per million per year (95% CI 8.7 - 14.3).
Eleven of 13 private neurologists in CT completed the 
questionnaire. Of these, 1 never used the assay and 5 routinely 
performed the AChR assay; the remaining 5 estimated that 
they used the assay in 50% of cases of suspected MG (N = 1), 
66% of cases (N = 1), and 80% of cases (N = 3).  We estimated 
that an additional 8 patients would have been diagnosed with 
SPMG by these doctors if the assay had been performed in all 
patients. Hence the adjusted total number of SPMG subjects in 
the study period from CT was 73, with an adjusted overall IR 
of 12.6 cases per million/year (95% CI 9.9 - 15.9).  
The non-adjusted IR among females in CT was 15.3 per 
million/year (95% CI 11.2 - 20.4) compared with 6.84 per 
million/year (95% CI 4.12 - 10.7) among males.  Among CT 
patients younger than 50 years, the IR was 6.5 per million/year 
(95% CI 4.4 - 9.2), whereas among patients older than 50, the 
IR was 38.7 per million/year (95% CI 26.6 - 54.3), with an IRR 
of 6.0 (95% CI 3.7 - 9.7). Fig. 1 shows the CT cohort age-specific 
IRs by gender. Among those with disease onset before 40 years 
there is a consistent, albeit modest, higher IR for females, with 
a larger peak between 65 and 74 years. Annual IRs for CT 
males peaked from 65 to 74 years, and then again over age 
85 years; the latter has a very wide CI (IR = 39.2, 95% CI 1.0 - 
218.5) owing to the small sample size.  However, in the CT 
cohort there was no statistically significant gender difference in 
the IRR comparing males with females in either those under 50 
years or those over 50 years at disease onset.  Although most 
of the CT males (63%) developed SPMG after the age of 50, the 
majority (62%) of the late-onset group were female.   
Most of the CT data originated from the teaching hospitals 
(N = 44) and the race of these patients was known.  Analysis of 
race after adjusting for age and gender showed an IR of 9.1 per 
million/year (95% CI 5.7 - 12.6) for coloured subjects, 4.2 per 
Fig. 1. Age- and sex-specific annual incidence rates (IRs) for subjects 
with seropositive myasthenia gravis in Cape Town (2003 - 2004).
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Fig. 1. Age- and sex-specific [U1]annual incidence rates (IRs) for subjects with seropositive
myasthenia gravis in Cape Town (2003 - 2004).
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million/year (95% CI 1.0 - 7.0) for blacks, and 5.0 per million/
year (95% CI 0.9 - 9.2) for whites. No statistically significant IR 
differences were found within race (p ≥ 0.14). Four thymomas 
(9%) were diagnosed during the study period.    
The number of positive assays nationally was 230. This 
included 41 positive assays, out of a total of 138 samples, 
performed by the Oxford laboratory.  The crude annual IR for 
SA nationally was 2.6 per million (95% CI 2.2 - 2.9), using a 
denominator for the population of South Africa of 44 819 770.12 
The age at which AChR testing was requested nationally (Fig. 
2) shows mostly females in the early-onset MG group and 
slightly more males in the late-onset group.
Discussion
The annual IR for SPMG in the CT municipal area, as averaged 
for the period 2003 - 2004, is comparable with recent incidence 
rates reported from Greece13 but lower than the IRs for SPMG 
in Spain and the UK6,8 (Table I).  The worldwide trend of 
increasing diagnosis of late-onset SPMG was also reflected in 
the CT cohort, with a 6 times greater annual IR among those 
with onset after the age of 50 years compared with earlier 
onset.  However, the CT results do not reflect the relatively 
greater annual IR for older men, seen elsewhere.8,9 The IRs for 
older CT females (Fig. 1) are similar to those reported from 
the UK (75 - 79-year-old IR = 4.8/100 000/year).8  However, 
the inconsistent and lower-than-expected IRs for older CT 
males (Fig. 1) are probably due to bias resulting from a 
smaller cohort, which is supported by the very wide 95% CIs 
for older males.  Also, in the larger national SA sample (Fig. 
2), late-onset SPMG case numbers peak over those of earlier 
onset, with slightly more males than females among late-onset 
subjects, consistent with findings in other populations.6,8
It has been postulated that the differences in IR between 
European countries do not reflect secular trend of disease 
but are due to differences in the accessibility of specialist 
health services.7,13  Regional health care delivery is likely to 
be a major contributing factor in the difference between the 
crude annual IR of SPMG in SA, and that in CT; the latter is 
more than 4 times higher than the IR of the country overall. 
The IR for SA overall was similar to the rate reported from a 
developing country, viz. Estonia,7 and far lower than the IRs of 
developed countries (Table I). The rural population in SA has 
limited access to secondary and tertiary health care, and we 
would predict significant underdiagnosis of MG in this sector.  
In a report from Kalafong Hospital, Pretoria, only 26 patients 
were consecutively diagnosed with MG over a 12-year period 
(1986 - 1998), and of the 9 patients tested for AChR antibodies, 
only 5 were positive.14 Unfortunately, racial data were 
available only for patients attending the CT tertiary academic 
hospitals, comprising about half of all the CT patients; there 
were no significant differences between age- and sex-adjusted 
incidence rates among racial groups. However, not only were 
the subgroups too small to provide meaningful data, but race-
related referral patterns would be likely to introduce bias.
SA has been recognised as having one of the most 
inequitable health services in the world15 and so it is not 
surprising to find significant regional variation in the reported 
incidence of an uncommon disease.  In 2003, the number of 
public-sector medical practitioners per 100 000 population 
in the Western Cape was the highest in the country at 31.9, 
with a national average of 19.7.  In contrast, the North West 
Fig. 2. Age at which AChR-positive tests were requested in SA 
nationally (2003 - 2004) (46 cases were not plotted as ages were not 
known).
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Fig. 2. Age at which AChR-positive tests were requested in SA nationally (2003 -
2004) (46 cases were not plotted as ages were not known).[U1]
Table I. Comparison of the annual incidence rates (IR) of myasthenia gravis in different countries
Country (year)   IR/million/year (95% CI)   Method of diagnosis
Estonia (1970 - 1996)7  4.0 (3.4 - 4.7)    Clin/pharm*
Greece (1992 - 1997)13  7.4 (6.5 - 8.3)    Clin/pharm/RNS*
Spain (1991 - 2000)6   21.3 (18.9 - 31.2)    Clin/pharm/RNS/AChR*
UK (1997 - 1999)8   18.0 (UK)     AChR antibody test – no confirmation of  
         clinical status
Cape Town        AChR
South Africa overall        AChR antibody test –  no confirmation of
(2003 - 2004)   11.2† (8.7 - 14.3) 2.6 (2.2 - 2.9)   clinical status
               
*Includes seronegative cases.
†Unadjusted IR for Cape Town.
Clin = diagnosis based only on fatiguable muscle weakness; pharm = positive Tensilon test; AChR = positive acetylcholine receptor antibody assay; RNS = >10% decremental response 
on repetitive nerve stimulation. 
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province had 11.5 public-sector medical practitioners per 
100 000 population.15  It is perhaps not surprising that a high 
concentration of public health care professionals influences the 
trend for diagnosis of this treatable disorder.  
In addition, there may be regional differences in diagnostic 
practice, perhaps partly due to the emphasis placed on the role 
of the AChR antibody test by the CT region academic centres 
and private neurologists.  In the absence of a standardised 
diagnostic protocol, some physicians and neurologists may 
rely predominantly on clinical or pharmacological diagnostic 
methods, and may not measure AChR antibodies routinely. 
The morbidity and mortality of untreated MG is significant, 
and in many instances treatment will necessitate protracted 
immunosuppressive therapy.  The clinical diagnosis is 
often not clear-cut, especially without access to specialised 
pharmacological or electrophysiological testing.  In our hands, 
a number of patients initially presumed to have MG were 
later diagnosed with motor neurone disease, oculopharyngeal 
muscular dystrophy, or mitochondrial or thyroid myopathy (J 
Heckmann – personal observation).  Senile ptosis or dehiscence 
of the tarsal plate may be asymmetrical, and can be confused 
with an ocular MG presentation.  This may be the reason why 
some neurologists (we presume) tend to have a low threshold 
for requesting the AChR antibody assay, resulting in a large 
proportion of negative assay results.  
Diagnostic tests available for MG include the ice test, 
pharmacological tests (Tensilon/neostigmine), AChR 
assay, repetitive nerve stimulation (RNS), and single-fibre 
electromyography (SFEMG).  The ice test may be useful in 
the diagnosis of ocular MG, but is not specific.2 Tensilon 
(edrophonium) has not been available in SA for some time, 
and neostigmine (intramuscular delivery) may be used 
instead.  However, as this has a longer duration of action, the 
patient must be monitored for at least an hour, which may 
not be possible in many settings.  RNS and SFEMG are not 
readily available at most health centres in SA, and moreover 
are time-consuming and can involve considerable technical 
difficulties.  The AChR is a relatively expensive radio-isotope 
immunoassay, but the major benefits would be to confirm the 
diagnosis, as it is highly specific for MG,1,2 and to indicate that 
a thymoma may be present.  Approximately 10 - 15% of SPMG 
patients have a thymoma, as was found in the CT cohort, and 
almost all these will need to be removed surgically.  A positive 
assay therefore underscores the need to exclude the possibility 
of thymoma using computed tomography of the chest, 
particularly in the older patient in whom thymectomy is not 
routinely considered as a treatment option for the myasthenic 
syndrome itself.16  
It is a limitation of this study that we do not know the 
proportion of SA patients outside the Cape Town municipality 
who may have SPMG but who have not had a confirmatory 
test, either because of diagnostic practice or financial 
constraints in the public or private sector.  Furthermore, we 
do not know the extent of underdiagnosis, or the lack of 
access to specialist health care.  Another potential drawback, 
albeit probably not significant, is the degree of inaccuracy 
introduced by using population statistics from 2001, before 
the study period (2003 - 2004).  If we assume positive growth 
and an increase in the denominator, the bias may increase the 
incidence of MG slightly. 
A preponderance of late-onset MG is noted in SA, and CT 
in particular shows approximately 6 times the number of late-
onset cases as those presenting earlier.  This is in agreement 
with the outcome of epidemiological studies conducted in 
countries such as Denmark, Spain and the UK.4,6,8  The reason 
for the higher incidence of target-organ autoimmune disease 
(such as MG) among the elderly is unknown, but Somnier4 
postulated that it may be due to environmental triggers such as 
chemical, infectious or tumour antigens.
In conclusion, the IR of SPMG in CT is somewhat lower than 
rates in recent reports from developed countries such as Spain 
and the UK, but is significantly higher than in the rest of SA.  
These differences are likely to reflect inadequate and unevenly 
distributed specialist health care and laboratory services in 
SA, and possibly lower numbers of elderly individuals in the 
disadvantaged socio-economic groups.  MG is a potentially 
fatal yet treatable disease.  Our report suggests that this disease 
may be under-recognised in this country.  In addition, the CT 
data confirm a similar trend to that in the rest of the world, and 
underscore the need for health practitioners to consider MG as 
a treatable disease in the elderly.  
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